

# Mauro Alaibac

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/729352/publications.pdf>

Version: 2024-02-01

152  
papers

2,439  
citations

279798

23  
h-index

254184

43  
g-index

156  
all docs

156  
docs citations

156  
times ranked

3205  
citing authors

#	ARTICLE	IF	CITATIONS
1	Near-infrared photoimmunotherapy for the treatment of skin disorders. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 509-517.	3.1	0
2	Trauma of Peripheral Innervation Impairs Content of Epidermal Langerhans Cells. <i>Diagnostics</i> , 2022, 12, 567.	2.6	2
3	Relationship between hair shedding and systemic inflammation in COVID-19 pneumonia. <i>Annals of Medicine</i> , 2022, 54, 869-874.	3.8	3
4	Altitude Effect on Cutaneous Melanoma Epidemiology in the Veneto Region (Northern Italy): A Pilot Study. <i>Life</i> , 2022, 12, 745.	2.4	0
5	Use of granulocyte and monocyte adsorption apheresis in dermatology (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	1.8	7
6	Skin cancers in Italian lung transplant recipients: Incidence and risk factors analysis. <i>Dermatologic Therapy</i> , 2021, 34, e14749.	1.7	0
7	Italian expertâ€based recommendations on the use of photo(chemo)therapy in the management of mycosis fungoides: Results of an eâ€Delphi consensus. <i>Photodermatology Photoimmunology and Photomedicine</i> , 2021, 37, 334-342.	1.5	4
8	Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma. <i>European Journal of Dermatology</i> , 2021, 31, 99-100.	0.6	1
9	Association between melanoma and exposure to sex hormones in puberty: A possible window of susceptibility (Review). <i>Molecular and Clinical Oncology</i> , 2021, 14, 66.	1.0	4
10	Melanoma of Unknown Primary: Evaluation of the Characteristics, Treatment Strategies, Prognostic Factors in a Monocentric Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 627527.	2.8	4
11	Management of melanoma patients during COVIDâ€19 pandemic in an Italian skin unit. <i>Dermatologic Therapy</i> , 2021, 34, e14908.	1.7	14
12	A rare case of earlyâ€onset lymphomatoid papulosis refractory to brentuximab vedotin. <i>Dermatologic Therapy</i> , 2021, 34, e14943.	1.7	1
13	Complete remission of primary cutaneous anaplastic large cell lymphoma after a short course of brentuximab vedotin. <i>Molecular and Clinical Oncology</i> , 2021, 14, 121.	1.0	3
14	Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report. <i>Frontiers in Medicine</i> , 2021, 8, 570921.	2.6	2
15	Management of PD-1/PD-L1 blockade immune-related skin toxicities: perspectives and issues. <i>Immunotherapy</i> , 2021, 13, 795-798.	2.0	0
16	Melanoma in Adolescents and Young Adults: Evaluation of the Characteristics, Treatment Strategies, and Prognostic Factors in a Monocentric Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 725523.	2.8	2
17	Bullous pemphigoid: An immune disorder related to aging (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 23, 50.	1.8	19
18	The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 1099-1107.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Merkel Cell Carcinoma: Evaluation of the Clinico-Pathological Characteristics, Treatment Strategies and Prognostic Factors in a Monocentric Retrospective Series (n=143). <i>Frontiers in Oncology</i> , 2021, 11, 737842.	2.8	6
20	In vitro Assessment of Solar Filters for Erythropoietic Protoporphyrin IX in the Action Spectrum of Protoporphyrin IX. <i>Frontiers in Medicine</i> , 2021, 8, 796884.	2.6	2
21	Leukocytoclastic vasculitis associated with multifocal sensory neuropathy responsive to intravenous immunoglobulins: a case report. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2021, 38, e2021022.	0.2	0
22	Eruptive Melanocytic Nevi Secondary to Encorafenib for BRAF Mutant Metastatic Colorectal Cancer. <i>In Vivo</i> , 2020, 34, 441-445.	1.3	5
23	Primary Cutaneous B-Cell Lymphomas in Patients With Impaired Immunity. <i>Frontiers in Oncology</i> , 2020, 10, 1296.	2.8	5
24	PD-1 gene rs2227981 (PD-1.5) polymorphism analysis in patients with systemic sclerosis. <i>Gene Reports</i> , 2020, 20, 100776.	0.8	0
25	Programmed cell death-1 rs2227981 polymorphism in patients with autoimmune skin blistering disorders: A pilot study. <i>Meta Gene</i> , 2020, 26, 100793.	0.6	2
26	A Monocentric Retrospective Observational Study of Comorbidities in Patients Affected by Autoimmune Bullous Diseases. <i>In Vivo</i> , 2020, 34, 2113-2118.	1.3	3
27	Melanoma Inhibitory Activity (MIA) Is Able to Induce Vitiligo-Like Depigmentation in an in vivo Mouse Model by Direct Injection in the Tail. <i>Frontiers in Medicine</i> , 2020, 7, 430.	2.6	5
28	Bullous pemphigoid and renal graft rejection: is there a causative link?. <i>European Journal of Dermatology</i> , 2020, 30, 441-442.	0.6	2
29	Editorial: Cutaneous B-Cell Lymphomas. <i>Frontiers in Oncology</i> , 2020, 10, 619709.	2.8	0
30	Near infrared photoimmunotherapy targeting the cutaneous lymphocyte antigen for mycosis fungoides. <i>Expert Opinion on Biological Therapy</i> , 2020, 21, 1-5.	3.1	8
31	Small-molecule-based immunotherapy for immunologically mediated skin conditions. <i>Immunotherapy</i> , 2020, 12, 417-429.	2.0	4
32	How to Deal With Post-viral Cutaneous Eruptions in the Era of Coronavirus Infection. <i>Frontiers in Medicine</i> , 2020, 7, 224.	2.6	2
33	Diagnostic Workup of Primary Cutaneous B Cell Lymphomas: A Clinician's Approach. <i>Frontiers in Oncology</i> , 2020, 10, 988.	2.8	4
34	Ultra-low dose rituximab for refractory pemphigus vulgaris: a pilot study. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 673-678.	3.1	18
35	Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 275-282.	3.1	8
36	A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 529.	2.8	8

#	ARTICLE	IF	CITATIONS
37	Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera. In <i>Vivo</i> , 2019, 33, 1667-1669.	1.3	12
38	Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report. <i>Experimental and Therapeutic Medicine</i> , 2019, 18, 2746-2748.	1.8	1
39	Electrochemotherapy of superficial tumors – Current status:. <i>Seminars in Oncology</i> , 2019, 46, 173-191.	2.2	80
40	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 332-342.	5.6	16
41	Recent advances in localized immunotherapy of skin cancers. <i>Immunotherapy</i> , 2019, 11, 443-456.	2.0	2
42	Topical imiquimod-induced linear IgA bullous dermatosis. <i>BMJ Case Reports</i> , 2019, 12, e230037.	0.5	2
43	Two-years of home based functional electrical stimulation recovers epidermis from atrophy and flattening after years of complete Conus-Cauda Syndrome. <i>Medicine (United States)</i> , 2019, 98, e18509.	1.0	13
44	Reflectance Confocal Microscopy in Evaluating Skin Cancer: A Clinicians's Perspective. <i>Frontiers in Oncology</i> , 2019, 9, 1457.	2.8	5
45	Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease. <i>BioMed Research International</i> , 2019, 2019, 1-7.	1.9	11
46	Immunomodulation in Cutaneous T Cell Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1025.	2.8	1
47	Biological Approaches to Aggressive Cutaneous B-Cell Lymphomas. <i>Frontiers in Oncology</i> , 2019, 9, 1238.	2.8	8
48	Biochip detection of BP180 autoantibodies in blister fluid for the serodiagnosis of bullous pemphigoid. <i>Medicine (United States)</i> , 2019, 98, e14514.	1.0	5
49	Biological therapy of autoimmune blistering diseases. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 149-156.	3.1	7
50	Case Report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy. <i>F1000Research</i> , 2019, 8, 336.	1.6	4
51	Eczematous, Pruritic, Brownish Plaque of the Nipple and Areola: A Quiz. <i>Acta Dermato-Venereologica</i> , 2019, 99, 1317-1318.	1.3	2
52	Comorbidities in Autoimmune Skin Diseases. <i>JAMA Dermatology</i> , 2018, 154, 264.	4.1	0
53	Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma. <i>Scientifica</i> , 2018, 2018, 1-7.	1.7	14
54	<i>Citrobacter freundii</i> sepsis in an immunosuppressed patient with pemphigus vulgaris. <i>BMJ Case Reports</i> , 2018, 11, e227091.	0.5	9

#	ARTICLE	IF	CITATIONS
55	Prognostic Factors in Merkel Cell Carcinoma: A Retrospective Single-Center Study in 90 Patients. <i>Cancers</i> , 2018, 10, 350.	3.7	17
56	Cutaneous squamous cell carcinoma. Italian Guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 747-762.	0.8	22
57	Ultra-Low Dosage Regimen of Rituximab in Autoimmune Blistering Skin Conditions. <i>Frontiers in Immunology</i> , 2018, 9, 810.	4.8	18
58	Small molecule inhibitors for cutaneous T-cell lymphomas. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 345-350.	0.8	0
59	Pustular eruption associated with granulocyte colony-stimulating factor treatment. <i>Italian Journal of Dermatology and Venereology</i> , 2018, 153, 276-277.	0.2	0
60	Immunotherapy-related skin toxicity: bullous pemphigoid in a lung adenocarcinoma patient treated with the anti-PDL1 antibody atezolizumab. <i>European Journal of Dermatology</i> , 2017, 27, 205-208.	0.6	18
61	Monoclonal antibodies against cutaneous T-cell lymphomas. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1503-1510.	3.1	6
62	Evaluation of anti-desmoglein-1 and anti-desmoglein-3 autoantibody titers in pemphigus patients at the time of the initial diagnosis and after clinical remission. <i>Medicine (United States)</i> , 2017, 96, e8801.	1.0	16
63	Basal cell carcinoma: 10-year experience with electrochemotherapy. <i>Journal of Translational Medicine</i> , 2017, 15, 122.	4.4	46
64	Successful treatment of pyoderma gangrenosum with granulocyte and monocyte adsorption apheresis. <i>International Wound Journal</i> , 2017, 14, 282-284.	2.9	8
65	Livedoid eruption in a patient affected by T-β <sub>2</sub> large granular lymphocyte leukaemia. <i>BMJ Case Reports</i> , 2017, 2017, bcr-2017-220051.	0.5	0
66	Interaction between Merkel cell carcinoma and the immune system: Pathogenetic and therapeutic implications. <i>Molecular and Clinical Oncology</i> , 2017, 7, 729-732.	1.0	5
67	Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases. <i>Journal of Translational Medicine</i> , 2017, 15, 227.	4.4	10
68	A comparative study of the cutaneous side effects between BRAF monotherapy and BRAF/MEK inhibitor combination therapy in patients with advanced melanoma: a single-centre experience. <i>European Journal of Dermatology</i> , 2017, 27, 482-486.	0.6	10
69	A Case of Angioinvasive Cutaneous Anaplastic Large Cell Lymphoma Completely Regressed After Low-dose Systemic Methotrexate. <i>Acta Dermato-Venereologica</i> , 2017, 97, 281-282.	1.3	0
70	Atrophic pityriasis versicolor occurring in a patient with Sjögren's syndrome. <i>BMJ Case Reports</i> , 2017, 2017, bcr2016218108.	0.5	5
71	Salivary Samples for the Diagnosis of Pemphigus vulgaris Using the BIOCHIP Approach: a Pilot Study. <i>In Vivo</i> , 2017, 31, 97-100.	1.3	9
72	A case of psoriasis pustulosa palmaris induced by cetuximab. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016214582.	0.5	5

#	ARTICLE	IF	CITATIONS
73	Increased risk of venous thromboembolism in patients with bullous pemphigoid. <i>Thrombosis and Haemostasis</i> , 2016, 115, 193-199.	3.4	30
74	TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma. <i>Oncology Letters</i> , 2016, 12, 275-280.	1.8	6
75	Toll-like receptors and cutaneous melanoma. <i>Oncology Letters</i> , 2016, 12, 3655-3661.	1.8	5
76	Atypical skin reaction in a patient treated with gefitinib for advanced lung cancer: A case report and review of the literature. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 197-200.	1.8	7
77	The use of Biochip immunofluorescence microscopy for the serological diagnosis of epidermolysis bullosa acquisita. <i>Archives of Dermatological Research</i> , 2016, 308, 273-276.	1.9	20
78	Association between Toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma. <i>Biomedical Reports</i> , 2016, 4, 459-462.	2.0	9
79	Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers. <i>Cancer Medicine</i> , 2016, 5, 2740-2755.	2.8	34
80	Radiodermatitis after spinal arteriovenous fistula embolisation. <i>BMJ Case Reports</i> , 2016, 2016, bcr2016214384.	0.5	2
81	TLR7 Gln11Leu single nucleotide polymorphism and response to treatment with imiquimod in patients with basal cell carcinoma: a pilot study. <i>Pharmacogenomics</i> , 2015, 16, 1913-1917.	1.3	10
82	Vitamins and Melanoma. <i>Cancers</i> , 2015, 7, 1371-1387.	3.7	22
83	Multiple Autoimmune Skin Manifestations in a Patient with Crohn's Disease Treated with a Tumor Necrosis Factor-Alpha Blocker. <i>Annals of Dermatology</i> , 2015, 27, 612.	0.9	0
84	Epidermolysis bullosa acquisita in a 17-year-old boy with Crohn's disease. <i>BMJ Case Reports</i> , 2015, 2015, bcr2015210210.	0.5	8
85	Rejection-mediated Regression of Melanocytic Naevi in an Immunosuppressed Organ Transplant Recipient. <i>Acta Dermato-Venereologica</i> , 2014, 94, 733-734.	1.3	0
86	The use of biochip immunofluorescence microscopy for the diagnosis of Pemphigus vulgaris. <i>Acta Histochemica</i> , 2014, 116, 713-716.	1.8	29
87	Psoriasis induced by thalidomide in a patient with multiple myeloma. <i>BMJ Case Reports</i> , 2014, 2014, bcr2014204469-bcr2014204469.	0.5	3
88	Exacerbation of a Primary Follicular Centre Cutaneous B-cell Lymphoma during Pregnancy and Resolution to Anetoderma After Delivery. <i>Acta Dermato-Venereologica</i> , 2014, 96, 828-9.	1.3	0
89	Response to "exchange" in dermoscopic pattern of naevi in children" by Scope et al. <i>Acta Dermato-Venereologica</i> , 2014, 94, 121-2.	1.3	0
90	Melanoma m1: diagnosis and therapy. <i>In Vivo</i> , 2014, 28, 273-85.	1.3	12

#	ARTICLE	IF	CITATIONS
91	Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. <i>In Vivo</i> , 2014, 28, 1005-11.	1.3	269
92	Role of alpha5beta1 integrin and MIA (melanoma inhibitory activity) in the pathogenesis of vitiligo. <i>Journal of Dermatological Science</i> , 2013, 71, 142-145.	1.9	7
93	Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: A pilot study. <i>Acta Histochemica</i> , 2013, 115, 767-769.	1.8	1
94	TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?. <i>Immunotherapy</i> , 2013, 5, 791-794.	2.0	2
95	Melanoma M (Zero): Diagnosis and Therapy. <i>ISRN Dermatology</i> , 2013, 2013, 1-10.	1.9	10
96	Analysis of p53 polymorphisms in individuals with multiple melanocytic nevi. <i>European Journal of Dermatology</i> , 2013, 23, 280-281.	0.6	0
97	Skin Cancer and Other Cutaneous Disorders in Liver Transplant Recipients. <i>Acta Dermato-Venereologica</i> , 2012, 92, 411-415.	1.3	34
98	Achromic Superficial Spreading Melanoma Accidentally Treated with Imiquimod. <i>Acta Dermato-Venereologica</i> , 2012, 92, 107-108.	1.3	6
99	Meyerson's phenomenon in a patient affected by high-risk melanoma under treatment with interferon- $\beta$ . <i>Melanoma Research</i> , 2012, 22, 284-285.	1.2	4
100	Biochip Technology for the Serological Diagnosis of Bullous Pemphigoid. <i>ISRN Dermatology</i> , 2012, 2012, 1-4.	1.9	30
101	Erosive Pustular Dermatitis of the Scalp Induced by Imiquimod. <i>Case Reports in Dermatological Medicine</i> , 2012, 2012, 1-2.	0.3	16
102	Occurrence of Squamous Cell Carcinoma in an Area of Lichen Simplex Chronicus: Case Report and Pathogenetic Hypothesis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 350-352.	1.2	7
103	Excess of melanocytic nevi in a patient treated with natalizumab for multiple sclerosis. <i>European Journal of Dermatology</i> , 2012, 22, 416-417.	0.6	3
104	Erythroderma in the era of biological therapies. <i>European Journal of Dermatology</i> , 2012, 22, 167-171.	0.6	12
105	Time course, clinical pathways, and long-term hazards risk trends of disease progression in patients with classic mycosis fungoides. <i>Cancer</i> , 2012, 118, 5830-5839.	4.1	105
106	Porokeratosis ptychotropica. <i>European Journal of Dermatology</i> , 2011, 21, 416-417.	0.6	7
107	Facial basal cell carcinoma: Analysis of recurrence and follow-up strategies. <i>Oncology Reports</i> , 2011, 26, 1423-9.	2.6	22
108	An unusual association between erosive hand osteoarthritis and morphea. <i>Joint Bone Spine</i> , 2011, 78, 532-533.	1.6	5

#	ARTICLE	IF	CITATIONS
109	The role of immunohistochemical analysis in the diagnosis of parapsoriasis. <i>Acta Histochemica</i> , 2011, 113, 92-95.	1.8	8
110	Bullous Scabies Simulating Pemphigoid. <i>Journal of Cutaneous Medicine and Surgery</i> , 2011, 15, 55-57.	1.2	10
111	Adaptive Immune Responses in Primary Cutaneous Sarcoidosis. <i>Clinical and Developmental Immunology</i> , 2011, 2011, 1-6.	3.3	11
112	Primary Cutaneous Mantle Cell Lymphoma. <i>Acta Dermato-Venereologica</i> , 2011, 91, 474-475.	1.3	16
113	Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study. <i>Clinical Transplantation</i> , 2010, 24, 328-333.	1.6	12
114	Vohwinkel syndrome: treatment of pseudo-â€œinhum. <i>International Journal of Dermatology</i> , 2010, 49, 79-82.	1.0	26
115	Nevus Spilus and Melanoma: Case Report and Review of the Literature. <i>Journal of Cutaneous Medicine and Surgery</i> , 2010, 14, 85-89.	1.2	15
116	Imiquimod for the Treatment of Classical Kaposi's Sarcoma. <i>Acta Dermato-Venereologica</i> , 2010, 90, 417-418.	1.3	11
117	Non-alcoholic fatty liver disease, alcohol intake and psoriasis. <i>Journal of Hepatology</i> , 2010, 53, 587.	3.7	6
118	Detection of Autoantibodies against Recombinant Desmoglein 1 and 3 Molecules in Patients with Pemphigus vulgaris: Correlation with Disease Extent at the Time of Diagnosis and during Follow-Up. <i>Clinical and Developmental Immunology</i> , 2009, 2009, 1-6.	3.3	54
119	Bullous Pemphigoid during Long-Term TNF-Î± Blocker Therapy. <i>Dermatology</i> , 2009, 219, 357-358.	2.1	56
120	Acne Keloidalis of the Scalp in a Renal Transplant Patient Treated with Cyclosporine. <i>Acta Dermato-Venereologica</i> , 2009, 89, 312-313.	1.3	8
121	Clinical tip: use of a manual dermatoscope with a compact digital camera in a pigmented lesion clinic. <i>Skin Research and Technology</i> , 2009, 15, 511-513.	1.6	0
122	Melanoma in skin affected with keratoderma palmoplantaris hereditaria (Mal de Meleda): Treatment with excision and grafting. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 161-163.	1.2	15
123	Effectiveness of different substrate materials for in vitro sunscreen tests. <i>Journal of Dermatological Science</i> , 2009, 56, 89-98.	1.9	27
124	Immunosuppression and melanocyte proliferation. <i>Melanoma Research</i> , 2009, 19, 63-68.	1.2	61
125	Large plaque type blue nevus with subcutaneous cellular nodules. <i>European Journal of Dermatology</i> , 2009, 19, 287-287.	0.6	15
126	Is SÃ©zary syndrome a true primary cutaneous lymphoma?. <i>International Journal of Dermatology</i> , 2008, 47, 1195-1196.	1.0	3



#	ARTICLE	IF	CITATIONS
127	Sunscreen tests: Correspondence between in vitro data and values reported by the manufacturers. <i>Journal of Dermatological Science</i> , 2008, 52, 193-204.	1.9	36
128	Subcorneal Pustular Dermatitis (Sneddon-Wilkinson Disease) with Absence of Desmoglein 1 and 3 Antibodies. <i>American Journal of Clinical Dermatology</i> , 2008, 9, 51-55.	6.7	21
129	Primary Subcutaneous B-cell Lymphoma: Case Report and Literature Review. <i>Acta Dermato-Venereologica</i> , 2008, 88, 151-154.	1.3	6
130	Î³Î³ T cells as potential contributors to the progression of parapsoriasis to mycosis fungoides. <i>Molecular Medicine Reports</i> , 2008, 1, 485-8.	2.4	1
131	Analysis of immunoglobulin variable kappa gene mutations in cutaneous B-cell lymphoma. <i>Journal of Dermatological Science</i> , 2007, 47, 248-252.	1.9	0
132	Clinical and dermatoscopic fading of post-transplant eruptive melanocytic nevi after suspension of immunosuppressive therapy. <i>Journal of the American Academy of Dermatology</i> , 2006, 54, 338-340.	1.2	30
133	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. <i>Experimental Dermatology</i> , 2006, 15, 958-965.	2.9	29
134	The role of Î³Î³ T cells in human cutaneous oncology. <i>Expert Review of Dermatology</i> , 2006, 1, 293-301.	0.3	0
135	Prognostic Factors in Primary Cutaneous B-Cell Lymphoma: The Italian Study Group for Cutaneous Lymphomas. <i>Journal of Clinical Oncology</i> , 2006, 24, 1376-1382.	1.6	199
136	Expression of the CD1a molecule in B- and T-lymphoproliferative skin conditions. <i>Oncology Reports</i> , 2006, 15, 347-51.	2.6	24
137	Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease. <i>Melanoma Research</i> , 2005, 15, 223-224.	1.2	18
138	C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. <i>Transplant International</i> , 2005, 18, 116-124.	1.6	27
139	Skin disorders in patients transplanted in childhood. <i>Transplant International</i> , 2005, 18, 360-365.	1.6	17
140	High-dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis-like T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, S121-S123.	1.2	27
141	Immunosuppressive Level and Other Risk Factors for Basal Cell Carcinoma and Squamous Cell Carcinoma in Heart Transplant Recipients. <i>Archives of Dermatology</i> , 2004, 140, 1079-85.	1.4	105
142	In situ expression of LAT (linker for activation of T cells) in pathological human skin with T-lymphoid infiltrate. <i>Archives of Dermatological Research</i> , 2004, 296, 231-234.	1.9	0
143	Eruptive melanocytic nevi in patients with renal allografts: Report of 10 cases with dermoscopic findings. <i>Journal of the American Academy of Dermatology</i> , 2003, 49, 1020-1022.	1.2	65
144	CD7 expression in reactive and malignant human skin T-lymphocytes. <i>Anticancer Research</i> , 2003, 23, 2707-10.	1.1	20

#	ARTICLE	IF	CITATIONS
145	Absent or low expression of T-cell receptor $\hat{\Gamma}$ -chain in T cells infiltrating human pathological skin conditions. Archives of Dermatological Research, 2002, 294, 380-382.	1.9	2
146	The Expression Pattern of the AML1 Gene in Non-Hodgkin's B-Cell Lymphomas and Normal B Lymphocytes. Blood Cells, Molecules, and Diseases, 2000, 26, 186-192.	1.4	7
147	Skin cancer in heart transplant recipients: frequency and risk factor analysis. Journal of Heart and Lung Transplantation, 2000, 19, 249-255.	0.6	121
148	Functional defect in cells involved in Langerhans cell histiocytosis. Archives of Dermatological Research, 1995, 287, 627-631.	1.9	13
149	Angioimmunoblastic lymphadenopathy with dysproteinemia and dermal T-cell lymphoma. Cancer, 1994, 74, 1801-1807.	4.1	6
150	T-Lymphocytes bearing the $\hat{\Gamma}$ T-cell receptor in cutaneous lesions of langerhans' cell histiocytosis. Medical and Pediatric Oncology, 1993, 21, 347-349.	1.0	7
151	Purification of Functional Active Epidermal Langerhans Cells: A Simple and Efficient New Technique. Journal of Investigative Dermatology, 1992, 99, 237-240.	0.7	17
152	?? T-LYMPHOCYTES: RELEVANCE OF THE CURRENT STUDIES TO DERMATOLOGY. International Journal of Dermatology, 1992, 31, 157-159.	1.0	10